Farah Bardai

Farah Bardai, PhD, currently serves as the Director of In-Vivo Pharmacology at Scribe Therapeutics since April 2023. Prior experience includes a role as Senior Manager and Pharmacology Scientist II at Vertex Pharmaceuticals from March 2018 to April 2023, as well as a position as Scientist II at Exonics Therapeutics for a brief period in March 2018. Between July 2013 and March 2018, Farah Bardai worked as a Post Doctoral Fellow at Brigham and Women's Hospital and Harvard Medical School, focusing on the molecular and cellular pathways involved in neurodegenerative diseases, including Familial Parkinson’s Disease and tauopathies. Farah Bardai holds a PhD in Cellular and Molecular Biology, as well as a Master’s degree in Bioinformatics and Computational Biology, both obtained from The University of Texas at Dallas.